(Q34282654)

English

Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

systematic review

1 reference

based on heuristic

inferred from title

diabetic macular edema

1 reference

based on heuristic

inferred from title

author name string

Haiyan Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Xiaodong Sun

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Kun Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Xun Xu

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

25 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Current Eye Research

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

661-670

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Epidemiology of diabetes and diabetes-related complications.

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema.

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Meta-analysis and review on the effect of bevacizumab in diabetic macular edema

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Intravitreal anti-VEGF therapy with prompt or deferred laser compared with steroid with prompt laser and prompt laser alone for treatment of diabetic macular edema

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema

1 reference

https://api.crossref.org/works/10.3109%2F02713683.2012.675616

21 January 2018

Identifiers

10.3109/02713683.2012.675616

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34282654&oldid=1956250238"